March 13, 2026
Incyte in 2026 and Beyond: Focus, Momentum & Patient Impact
Following a strong 2025 where we delivered exceptional results across our business, advanced our pipeline and continued to make a meaningful difference for patients, Incyte moves into 2026 with real momentum and a clear plan for long-term growth and innovation.
Advancing Innovation Across Our Core Franchises
We continue to focus on three key franchises where we have differentiated knowledge and capabilities:
- Hematology is central to the identity of Incyte, specifically in the treatment of myeloproliferative neoplasms (MPNs), a group of rare blood cancers. We are developing several mutation-specific targeted therapies with the potential to address the treatment needs of 85% of the MPN population today.
- In Oncology, we’re focused on novel biologic targets and pathways in high-incidence cancers, including colorectal, pancreatic and ovarian cancer.
- Inflammation and Autoimmunity (IAI) includes topical-to-oral and mild to severe solutions for chronic immune-mediated dermatologic conditions, such as vitiligo, atopic dermatitis and hidradenitis suppurativa.
A Portfolio Designed for Scalable Impact
Across our three franchises, Incyte’s nine available medicines continue to make a difference for patients, with more than two million individuals around the world treated to date.
Alongside these treatments, Incyte’s robust pipeline is anchored by seven high-value and potentially transformative assets – axatilimab (anti-CSF-1R antibody), mutCALR monoclonal antibody (‘989), JAK2V617F small molecule, TGFβR2xPD-1 bispecific, KRASG12D inhibitor, CDK2 inhibitor and povorcitinib (JAK1 inhibitor). This novel pipeline provides a strong foundation for our ongoing innovation and growth together representing the potential for more than $10B in potential peak net sales by 2030.
2026 will be a defining year as we accelerate our pipeline and position the company for sustained growth. By year-end, we expect to have initiated 14 pivotal trials across these priority programs, alongside important Phase 3 and proof-of-concept study readouts that will shape our next wave of innovation. At the same time, we will execute on several anticipated launches across each of our franchises and pursue focused business development opportunities to strengthen and extend our core business.
We’ve made deliberate choices to concentrate on areas where we believe Incyte can bring meaningful innovation. Incyte enters 2026 with a strategically focused pipeline, strong business momentum and a clear strategy for long-term growth.
Follow along with our latest updates and announcements here: https://investor.incyte.com
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this story, including statements regarding the potential of our products and clinical candidates and our expectations for 2026, contain predictions, estimates, and other forward-looking statements.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the U.S. FDA and other regulatory authorities; the efficacy or safety of our partners’ products; the acceptance of our and our partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. We disclaim any intent or obligation to update these forward-looking statements.
